Lexaria Bioscience (LEXX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Lexaria Bioscience’s recent animal study reveals promising 12-week results for its DehydraTECH-liraglutide and select CBD formulations in enhancing weight loss, outperforming traditional GLP-1 drugs like semaglutide. The study, which focused on drug delivery innovations, showed accelerated weight loss in the final weeks, highlighting the potential of Lexaria’s technology in diabetes treatment.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
